923P Immune alterations in a window of opportunity for durvalumab (MEDI4736) plus metformin trial in squamous cell carcinoma of the head and neck (SCCHN)

Authors :: Uche Nwagu
Joseph Curry
Adam Luginbuhl
Jennifer Johnson
Rita Axelrod
Alban Linnenbach
Ulrich Rodeck
David Cognetti
Ralph Zinner
Ubaldo E. Martinez-Outschoorn
Athanassios Argiris
Richard A. Goldman
Larry Harshyne
Voichita Bar-Ad
N. Srivastava
Source :: Annals of Oncology. 31:S665-S666
Publication Year :: 2020
Publisher :: Elsevier BV, 2020.

Subjects :: Oncology
medicine.medical_specialty
Window of opportunity
Durvalumab
business.industry
Hematology
Metformin
Immune system
Internal medicine
medicine
Basal cell
Head and neck
business
medicine.drug

Tools